Tenax Therapeutics (TENX) Stock Price, News & Analysis

Company Overview

Tenax Therapeutics, Inc. is a clinical-stage specialty pharmaceutical company developing drug delivery technologies designed to improve pain management in acute care settings. The company’s proprietary platform leverages biodegradable polymer matrices to create sustained-release formulations of local anesthetics, aiming to extend the duration of pain relief while reducing reliance on opioid medications.

Tenax’s lead development programs focus on injectable formulations intended for infiltration and peripheral nerve block applications, with the goal of providing longer-lasting analgesia following surgical and procedural interventions. The company conducts preclinical and clinical studies under the guidance of U.S. Food and Drug Administration regulations and is advancing its most advanced candidates toward pivotal trials.

Headquartered in Exton, Pennsylvania, Tenax Therapeutics serves hospitals, surgery centers and other healthcare facilities primarily in North America. The company collaborates with academic institutions and strategic partners to advance its pipeline. Tenax is managed by a team of executives with backgrounds in pharmaceutical development and commercialization, and it is publicly traded on the NASDAQ under the ticker symbol TENX.

Key Stats

• Today's Range: $5.96 to $6.03
• 50-Day Range: $5.74 to $6.24
• 52-Week Range: $3.25 to $7.89
• Volume: 10,063 shs
• Average Volume: 15,904 shs
• Market Capitalization: $27.31 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $17.00
• Consensus Rating: Buy

Tenax Therapeutics Stock Analysis - MarketRank™

Tenax Therapeutics scored higher than 27% of companies evaluated by MarketBeat, and ranked 825th out of 928 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.8 / 5
• Analyst Rating: Buy

Consensus Rating

Tenax Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.25, and is based on 3 buy ratings, no hold ratings, and no sell ratings.

Upside Potential

Tenax Therapeutics has a consensus price target of $17.00, representing about 183.8% upside from its current price of $5.99.

Amount of Analyst Coverage

Tenax Therapeutics has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Tenax Therapeutics are expected to decrease in the coming year, from ($0.88) to ($3.30) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Tenax Therapeutics is -6.51, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Tenax Therapeutics is -6.51, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Tenax Therapeutics has a P/B Ratio of 0.22. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

7.90% of the float of Tenax Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Tenax Therapeutics has a short interest ratio ("days to cover") of 12.3, which indicates bearish sentiment.

Change versus previous month

Short interest in Tenax Therapeutics has recently decreased by 2.30%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Tenax Therapeutics does not currently pay a dividend.

Dividend Growth

Tenax Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

7.90% of the float of Tenax Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Tenax Therapeutics has a short interest ratio ("days to cover") of 12.3, which indicates bearish sentiment.

Change versus previous month

Short interest in Tenax Therapeutics has recently decreased by 2.30%, indicating that investor sentiment is improving.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

MarketBeat Follows

1 people have added Tenax Therapeutics to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Tenax Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 3.70% of the stock of Tenax Therapeutics is held by insiders.

Percentage Held by Institutions

Only 1.67% of the stock of Tenax Therapeutics is held by institutions.

TENX Stock Analysis - Frequently Asked Questions

How have TENX shares performed this year?

Tenax Therapeutics' stock was trading at $6.19 at the start of the year. Since then, TENX shares have decreased by 3.2% and is now trading at $5.99.

How were Tenax Therapeutics' earnings last quarter?

Tenax Therapeutics, Inc. (NASDAQ:TENX) issued its quarterly earnings data on Wednesday, August, 13th. The specialty pharmaceutical company reported ($0.27) EPS for the quarter, topping the consensus estimate of ($0.50) by $0.23.

When did Tenax Therapeutics' stock split?

Shares of Tenax Therapeutics reverse split on the morning of Wednesday, January 3rd 2024.The 1-80 reverse split was announced on Wednesday, January 3rd 2024. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, January 3rd 2024. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split.

How do I buy shares of Tenax Therapeutics?

Shares of TENX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Tenax Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Tenax Therapeutics investors own include Sangamo Therapeutics (SGMO), NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), CymaBay Therapeutics (CBAY), Broadcom (AVGO) and Novo Nordisk A/S (NVO).

Company Calendar

• Last Earnings: 8/13/2025
• Today: 9/07/2025
• Next Earnings (Estimated): 11/12/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:TENX
• CIK: 34956
• Web: www.tenaxthera.com
• Phone: 919-855-2100
• Fax: 919-855-2133
• Employees: 9
• Year Founded: 1967

Price Target and Rating

• Average Price Target for Tenax Therapeutics: $17.00
• High Price Target: $20.00
• Low Price Target: $14.00
• Potential Upside/Downside: +183.8%
• Consensus Rating: Buy
• Rating Score (0-4): 3.25
• Research Coverage: 4 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.92)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$17.60 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -31.34%
• Return on Assets: -30.39%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 41.89
• Quick Ratio: 41.89

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $26.99 per share
• Price / Book: 0.22

Miscellaneous

• Outstanding Shares: 4,560,000
• Free Float: 4,393,000
• Market Cap: $27.31 million
• Optionable: Not Optionable
• Beta: 1.44